Alabama Deep Sea Fishing Rodeo helps advance marine research
University of South Alabama professor Dr. Sean Powers has been judging the rodeo for 20 years, and he says there's a reason this specific event is so crucial to sea life studies here in South Alabama.
'Scientists aren't good fishermen,' Dr. Powers said. 'Just because we study it doesn't mean we're good fishermen. But these are the best fishermen.'
While Dr. Powers weighs the fish he sees, he's also taking some notes.
'The science footprint is just as big as the tournament,' he said. 'So, we have 100 young scientists out here that we're training and collecting data that's very, very useful for fisheries, management, and also training.'
With the help of University of South Alabama students, scientists are able to track all sorts of sea life patterns.
'We can also take that ear bone and run chemical analysis on it and see where that fish came from,' Dr. Powers explained. 'Did that fish come from Louisiana? That fish come from Florida, and all those things we can do because these fishermen are letting us sample their fish.'
It's a partnership Dr. Powers said he is extremely grateful for.
'It just the opportunity we wouldn't get normally without spending a tremendous amount of money,' he said. 'So we call this 'Fishmas' because all of them are bringing us presents every day.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Record number of injured birds brought in to University of Minnesota's Raptor Center
The University of Minnesota's Raptor Center says a record number of birds are being brought in for injuries. "It's been a record-setting year. And last year was a record-setting year," said Interim Executive Director Lori Arendt. During the summer months, it's not unusual to see an uptick in eagles, owls, and hawks being brought into the U of M's Raptor Center. What is unusual is the record pace at which they're being brought in. "This morning, we were at 679 for the year. And last year we were at about 550," said Arendt. "We have birds that are hit by cars, by windows, that get caught in buildings and are hit by ceiling fans." Arendt said weather is a big part of the uptick. A milder winter means more mice. And more mice means more food for raptors, which in turn, means the population soars. "Our baby season has just been really, really busy," said Arendt. Those same chicks have fallen victim to storms and high winds, which have knocked down raptor nests. The wet spring can be blamed for more cases of West Nile Virus among the birds. Some mosquitoes carry the virus and they've been thriving in this weather. "We've already admitted more than 40 birds that we suspect have succumbed to the virus," said Arendt. The Raptor Center said their facilities are nearly full, workers are getting overtime, and they are relying on volunteers to fill the gaps. With more birds coming into contact with vehicles and viruses, Arendt thinks this could be a sign of things to come. "We are really looking at how can we be prepared for this higher case load and higher number or raptors that we are admitting to our hospital. How can we be proactive, so we are better prepared for it," said Arendt. As of May 31, the Raptor Center had 80 raptor babies admitted into their clinic, which is 30 more than their record high during the spring of 2023.
Yahoo
an hour ago
- Yahoo
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
Investment will support AstraZeneca's ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company's largest single investment in a facility to date WILMINGTON, Del., July 21, 2025--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Continuous manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials Our growing research and development investment in novel medicines Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US. Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here." Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth." Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines." Notes AstraZeneca in the US The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy. Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade. AstraZeneca AstraZeneca (Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca. View source version on Contacts Media Inquiries Fiona Cookson +1 212 814 3923Rachel Ross +1 202 427 1621 US Media Mailbox: usmediateam@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Ultra-Processed Foods Linked To Overeating And Inflammation
Research continues to emerge showing the adverse health effects of consuming ultra-processed foods. While the exact definition can vary, ultra-processed foods, or UPFs, are typically foods that are calorically dense, higher in refined sugar, fat, and salt, low in fiber and other nutrients, and of course, highly processed. One problem with UPFs is that they tend to make people overeat. The high salt, fat, and carb combination can make them particularly easy to overconsume. Coupled with typically lower protein levels, these foods often fail to provide the same level of satiety as a similar number of calories from whole foods might offer. 'Experimental evidence demonstrates that the soft texture, high energy density and hyperpalatable nutrient combinations of UPF facilitate excessive energy intakes by affecting ingestive behaviours, satiety signalling and food reward systems,' read a July 14 study in Nature. Another study published in May in the Journal of Nutrition and Metabolism found a strong link between the consumption of ultra-processed foods and the presence of C-reactive protein (CRP). CPR is produced by the liver in response to inflammation and is associated with an increased risk of heart disease. The researchers also found that consuming UPFs drove a higher white blood cell count. 'These two biomarkers indicate that these foods are causing an inflammatory response in our bodies. In a sense, this suggests that our bodies are seeing these as non-foods, as some kind of other element,' said Anthea Christoforou, an assistant professor in the Department of Kinesiology at McMaster University and senior author of the paper. In short, UPFs may be harmful for a multitude of reasons: they cause us to overeat, trigger inflammation, and lack sufficient protein and nutritious vitamins and minerals. To make matters worse, these types of foods are heavily marketed and convenient. Children are particularly susceptible to nutrient-scarce, high-sugar items, such as cereal, prominently featured in grocery store aisles. The good news? Trials have shown that dropping even one daily serving of UPFs from your diet can help cut inflammatory markers. Solve the daily Crossword
